Citations

Clear

112 citation(s) found for "Schaefer, PL".

Neural Mechanisms of Listening to Speech in Noise With Age-Related Hearing Loss
Fitzhugh, Megan C. , Baxter, Leslie C. , Rogalsky, Corianne , Baxter, Leslie C. , Schaefer, Sydney Y.

Mayo Clinic

Ear & Hearing | December 26, 2025 | Volume: 47 | Issue: 3 | Pages: 652-661

10.1097/aud.0000000000001760 | PMID 41453009 Get It

Objective: Age-related hearing loss is prevalent in a large proportion of older adults and is the largest modifiable risk factor of dementia. Previous studies have shown that hearing loss in older adults is associated with reductions in brain volume and alterations in brain connectivity, but there is a gap in our understanding of how hearing loss may impact brain activity, specifically while listening to speech. In this study, we hypothesized that hearing loss would be associated with (1) reduced activation within temporal auditory regions in response to speech presented with and without background noise, and (2) increased activation in the cingulo-opercular network in response to speech in noise. Design: Twenty-seven older adults (mean age = 68 yr, 17 women) recruited from the community completed a clustered sparse-sampling functional magnetic resonance imaging protocol while listening to speech presented with and without multi-talker background noise. Regions of interest–based and exploratory voxel-wise analyses were used to investigate correlations between functional magnetic resonance imaging activation to speech and hearing ability. Hearing was defined as the pure-tone average of hearing thresholds at 0.5, 1, 2, and 4 kHz from the better ear and ranged from normal to a moderate hearing loss. Results: Our results indicate that age-related hearing loss was associated with reduced activation in right Heschl’s gyrus and left middle temporal gyrus in response to speech. Exploratory voxel-wise analyses suggest that hearing loss may be associated with alterations in activation in other sensory cortical regions and portions of the frontal cortex, including left pars opercularis. Activation within the cingulo-opercular network was not associated with hearing loss. Conclusions: These findings suggest that age-related hearing loss in humans is associated with altered brain activity in response to speech, particularly within right Heschl’s gyrus. It further provides hypothesis-generating data for future studies on the effects of hearing loss on brain function.
Foundations of systems-based hematology: thematic analysis of expert interviews to guide curriculums and promote growth
Godby, Richard , Cogan, Jacob C. , Cuker, Adam , García, David , Masias, Camila , May, Jori E. , Morton, Colleen , Shah, Surbhi , Zumberg, Marc , Marshall, Ariela L. , Godby, Richard Curtis , Lim, Ming Y , May, Jori , Schaefer, Jordan K , Shah, Surbhi , Zumberg, Marc S , Marshall, Ariela , Schaefer, Jordan K.

Mayo Clinic

Blood Advances | December 5, 2025 | Volume: 10 | Issue: 6 | Pages: 2038-2046

10.1182/bloodadvances.2025018748 | PMID 41348898 Get It

Abstract Systems-based hematology (SBH) is an emerging discipline focused on optimizing care delivery for patients with hematologic disorders within complex health care systems. Despite its growing importance, the field lacks a formal definition, standardized curriculum, and clear career pathway, hindering widespread adoption and training of future SBH experts. We sought to define core principles, competencies, challenges, and future directions of SBH to identify foundational components for a potential educational curriculum. Semistructured interviews were conducted with 8 SBH experts. Expert participants were identified through their committee involvement with the American Society of Hematology. Five overarching themes emerged: (1) The accidental expert: SBH careers have developed organically and reactively in response to pressing institutional needs, not through formal training; (2) Defining the unseen: experts define the field pragmatically by its function and roles; (3) The SBH toolkit: success requires a hybrid skillset combining clinical hematology expertise with health systems science (HSS) principles; (4) The architect's dilemma: the field's growth is hindered by interdependent challenges of building a curriculum, awareness, and securing resources; and (5) Charting the future: the discipline is poised for growth, driven by increasing health care complexity and specialization. SBH represents the nexus of HSS principles and hematology care. Formalizing SBH requires a multipronged approach, including developing a standardized curriculum that equips learners with a hybrid skillset, creating clear value for health systems and patients, and fostering a community of practice through professional societies. These findings provide a foundational framework for developing educational resources and institutional support necessary to continue advancing SBH.
ERRATUM: Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad
Haller, Florian , Moskalev, Evgeny A. , Barthelmeß, Sarah, Otto, Claudia , Rattenberry, Eleanor, Carney, J. Aidan, Hartmann, Arndt, Faucz, Fábio R. , Wiemann, Stefan , Bieg, Matthias , Assié, Guillaume , Bertherat, Jérôme , Schaefer, Inga‐Marie , Maher, Eamonn R. , Ströbel, Philipp , Werner, Martin , Hartmann, Arndt, Stratakis, Constantine A. , Agaimy, Abbas

Mayo Clinic

Endocrine-Related Cancer | July 21, 2025 | Volume: 32 | Issue: 7 | Pages: No page available

10.1530/erc-14-0254e | PMID 40686492 Get It

Abstract CT112: Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of FXX489 ([177Lu]Lu-NNS309) in patients with pancreatic, lung, breast and colorectal cancers
Geva, Ravit , Juneau, Daniel , Ferrario, Cristiano , Moradi, Farshad , Iravani, Amir , Ahnert, Jordi, Rúiz, I., Koessler, Thibaud, Ferrandiz, Aitana Calvo, Spéville, Bernard Doger de , Razak, Albiruni R. Abdul, Al-Mansour, Laure, Nienhuis, Hilde H. , Eiber, Matthias , Heuschkel, Martin, Geoffrey, J Lane, Origuchi, Shizuka, Couillebault, Xuan Mai, Garayoa, Elisa Garcı́a, Roopa, Jayarama Naidu, Straub, Christopher, Hainzl, Dominik, Chen, Xinyu , Yang, Fang , Pectasides, Eirini, Mancini, B.R. , Esfahani, Shadi A. , Ahnert, Jordi, Ruiz, Ivan Manuel Victoria, Ferrandiz, Aitana Calvo, Flamen, Patrick , Deandreis, Désirèe , Schaefer, Niklaus , Nagarajah, James , Maccauro, Marco , Filice, Angelina , Goldman, Jonathan W. , Hermann, Ken , Drzezga, Alexander E. , McConathy, Jonathan , Geoffrey, Johnson, Parent, Ephraim E. , Kuboki, Yasutoshi , Couillebault, Xuân-Mai

Mayo Clinic

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: CT112-CT112

10.1158/1538-7445.am2025-ct112 Get It

Abstract Background: Fibroblast activation protein (FAP) is a type II integral membrane glycoprotein, highly expressed on the cell surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers and showing limited expression in normal tissues. Given this expression profile, FAP appears to be a promising target for radioligand therapy that has pan-cancer potential. [177Lu]Lu-NNS309 is a FAP-targeted radiopharmaceutical that shows improved tumor retention and demonstrates promising anti-tumor activity in translationally relevant preclinical models (e.g., PDAC, NSCLC) where FAP is expressed on CAFs. Methods: CFXX489A12101 (NCT06562192) is a first-in-human phase I, open-label, multi-center study of [177Lu]Lu-NNS309 in patients with pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC). The study includes a dose escalation part followed by a dose expansion part. Key eligibility criteria include prior treatment for locally advanced unresectable or metastatic disease and having all measurable lesions (per RECIST 1.1) showing [68Ga]Ga-NNS309 uptake on positron emission tomography/computed tomography (PET/CT). Patients who are eligible for treatment receive one dose of [177Lu]Lu-NNS309 on day 1 of each cycle. A 6-week and a 4-week dosing schedule will be explored. Dosimetry data will be obtained from patients in the dose escalation part after the first dose and will be used to calculate the cumulative radiation exposure. Dose escalation will be guided by a Bayesian hierarchical logistic regression model with overdose control (EWOC) principle, and assessment of all relevant data available from all dose levels including safety, tolerability, clinical dosimetry, pharmacodynamics, and preliminary efficacy. Once the recommended dose(s) (RD) and schedule(s) of [177Lu]Lu-NNS309 are determined, the expansion part may open and will include patients with locally advanced or metastatic PDAC (n∼20), locally advanced or metastatic NSCLC (n∼20), HR+/HER2- ductal BC (n∼15), HR+/HER2- lobular BC (n∼15), and triple negative BC (; n∼24).The primary objectives of the study are to evaluate the safety and tolerability of [177Lu]Lu-NNS309 and to identify the RD(s) and regimen(s) of [177Lu]Lu-NNS309 for further clinical evaluation. Secondary objectives of the study are to evaluate the preliminary anti-tumor activity of [177Lu]Lu-NNS309, characterize the pharmacokinetics of [177Lu]Lu-NNS309 in blood and urine, the radiation dosimetry for organs and tumor lesions, and to evaluate the safety and imaging properties of [68Ga]Ga-NNS309. Conclusion: The study is currently enrolling in the dose escalation part. Citation Format: Ravit Geva, Daniel Juneau, Shadi Abdar Esfahani, Cristiano Ferrario, Farshad Moradi, Amir Iravani, Jordi Ahnert, Ivan Manuel Victoria Ruiz, Thibaud Koessler, Aitana Calvo Ferrandiz, Bernard Doger de Speville, Patrick Flamen, Albiruni Razak, Desiree Deandreis, Laure Al-Mansour, Niklaus Schaefer, James Nagarajah, Hilde Nienhuis, Marco Maccauro, Angelina Filice, Jonathan Goldman, Ken Herrmann, Matthias Eiber, Alexander Drzezga, Martin Heuschkel, Jonathan McConathy, Johnson Geoffrey, Ephraim Parent, Yasutoshi Kuboki, Shizuka Origuchi, Xuan Mai Couillebault, Elisa Garcia Garayoa, Jayarama Naidu Roopa, Christopher Straub, Dominik Hainzl, Xinyu Chen, Fang Yang, Eirini Pectasides, Brandon Mancini. Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of FXX489 ([177Lu]Lu-NNS309) in patients with pancreatic, lung, breast and colorectal cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT112.
Abstract 7331: Antitumor activity of amivantamab in diffuse pleural mesothelioma
Yang, Lin , Ayers-Ringler, Jennifer , Schaefer-Klein, Janet L., Kosari, Farhad , Suzuki, Shinichiro , Tolosa, Ezequiel J. , Wu, Kuan‐Li , Mansfield, Aaron S.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 7331-7331

10.1158/1538-7445.am2025-7331 Get It

Abstract Background: Diffuse pleural mesothelioma (DPM) is a rare and aggressive cancer arising from mesothelial cells of the pleura. Over 2, 500 new cases are diagnosed annually in the United States, mainly attributable to asbestos exposure. The prognosis is poor, and while nivolumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor) have been approved for first-line treatment of unresectable DPM, the three-year survival rate is only 23%. DPM tumors express high levels of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), but targeted therapies like erlotinib (EGFR tyrosine kinase inhibitors) have shown no clinical benefit. We hypothesized that amivantamab, a bispecific antibody that targets both EGFR and MET, may have activity against DPM through antibody-dependent cellular cytotoxicity (ADCC). Objective: The purpose of this study was to assess the potential of amivantamab to mediate ADCC in tissue culture experiments with DPM cell lines. Methods: We assessed DPM for the expression of EGFR and MET using available data from bulk RNA sequencing. We also examined protein expressions of EGFR and MET by Western blot analysis in five epithelial (EM-Meso, H2452, H2461, Mero-41 and Mero-95), three sarcomatoid (H2373, H2596 and ONE58), and one normal mesothelial (MeT-5A) cell lines. Co-culture experiments were performed with the DPM and normal cell lines and NK cells in the presence of amivantamab to evaluate ADCC. Results: We identified high levels of EGFR and MET expression in both epithelial and sarcomatoid cases of DPM from 183 patients. This finding was corroborated by Western blot analysis of all eight DPM cell lines. In vitro experiments demonstrated that amivantamab induced dose-dependent ADCC in DPM cell lines, with robust NK cell-mediated ADCC observed across all tested DPM lines. Notably, sarcomatoid-type DPM cells were more sensitive to amivantamab-induced ADCC than epithelial-type cells. These findings suggest that amivantamab may offer therapeutic benefits for DPM tumors with high EGFR and MET expression. Conclusion: This study provides preclinical evidence supporting the potential of amivantamab as a novel therapeutic option for DPM, especially in sarcomatoid tumors. Ongoing in vivo studies including in patient-derived xenograft (PDX) models will further evaluate the efficacy of amivantamab in DPM. Citation Format: Shinichiro Suzuki, Lin Yang, Jennifer Ayers-Ringler, Ezequiel J. Tolosa, Kuan-Li Wu, Janet L. Schaefer-Klein, Farhad Kosari, Aaron S. Mansfield. Antitumor activity of amivantamab in diffuse pleural mesothelioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7331.
Fluorescence based live cell imaging identifies exon 14 skipped hepatocyte growth factor receptor (MET) degraders
Yang, Lin , Lin, Wan-Hsin, Feathers, Ryan W. , Ayers-Ringler, Jennifer , Tolosa, Ezequiel J. , Kizhake, Amritha G., Kizhake, Smitha , Kubica, Sydney P., Boghean, Lidia , Naldrett, Michael J. , Rana, Sandeep , Schaefer-Klein, Janet, Roden, Anja C. , Kosari, Farhad , Anastasiadis, Panos Z. , Feathers, Ryan, Tolosa, Ezequiel, Roden, Anja, Natarajan, Amarnath , Mallareddy, Jayapal Reddy , Lin, Wan‐Hsin , Alvarez, Sophie , Singh, Sarbjit , Zahid, Muhammad , Borad, Mitesh J. , Natarajan, Amarnath , Mansfield, Aaron S.

Mayo Clinic

RSC Advances | April 4, 2025 | Volume: 15 | Issue: 13 | Pages: 10419-10425

10.1039/d5ra01441g | PMID 40182503 Get It

Despite ongoing efforts to employ structure-based methods to discover targeted protein degraders (TPD), the prevailing strategy remains synthesizing a focused set of heterobifunctional compounds and screening them for target protein degradation.
Defining and Developing a Curriculum for Systems-Based Hematology: A Qualitative Thematic Analysis of Expert Interviews
Cogan, Jacob C. , Cuker, Adam , García, David , Masias, Camila , Morton, Colleen , Shah, Surbhi , Zumberg, Marc , Godby, Richard , Lim, Ming Y , May, Jori E. , Schaefer, Jordan K. , Marshall, Ariela L.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3820-3820

10.1182/blood-2024-194644 Get It

Introduction: Systems-based hematology (SBH) is an emerging field focused on improving hematology care delivery through quality improvement (QI) and health systems science (HSS). However, a universal definition and standardized training curriculum are lacking. This study aimed to explore experts' perspectives on defining SBH, identify core knowledge and skills, and discuss challenges and opportunities in developing a curriculum. Methods: Semi-structured interviews were conducted with eight hematologists who have expertise in SBH through practical experience, scientific publications, and serve on related committees for the American Society of Hematology. These interviews were automatically transcribed through Microsoft Teams. Thematic analysis, using both inductive and deductive coding, was employed to identify themes and subthemes from the verbatim interview transcripts. This was accomplished with a large language model (LLM; Google Gemini Advanced, June 2024). Results: In combination, these semi-structured interviews lasted approximately 400 minutes and generated 231 pages of transcript text with 63117 words for analysis. Five main themes and associated subthemes were identified. (1) Defining SBH: experts highlighted the lack of a universal definition for SBH, emphasizing the reason it is often defined by its functions, such as improving healthcare delivery, ensuring appropriate use of resources, and addressing disparities in care. They often compared SBH to other fields like antimicrobial stewardship or implementation science to illustrate its expansive role and scope. (2) The Role and Scope of SBH: experts described SBH as encompassing a broad range of activities, including improving healthcare delivery, implementing QI initiatives, conducting pragmatic research, and advocating for policy changes at various levels. They emphasized the importance of data-driven approaches and collaboration with other healthcare professionals. (3) Training and Education in SBH: the lack of formal training programs and curricula for SBH was a recurring theme. Experts suggested that a comprehensive curriculum should include QI methodologies, implementation science, clinical informatics, health economics, leadership skills, and hematology-specific examples and case studies. They proposed various delivery methods, including asynchronous online modules, virtual workshops, and in-person sessions, targeting hematology fellows, junior faculty, and other healthcare professionals involved in hematology care. They unanimously agreed that a SBH curriculum could borrow heavily from an established HSS curriculum but should incorporate hematology-specific examples. (4) Challenges and Barriers to Implementing SBH: experts identified several challenges, including the lack of awareness and recognition of SBH among healthcare professionals and administrators, resource constraints, and the need for institutional buy-in. They also highlighted the technical difficulty of measuring and demonstrating the value of SBH interventions, particularly in terms of cost savings and improved patient outcomes. (5) The Future of SBH: despite the challenges, experts expressed optimism about the future of SBH, predicting its growing importance and expanding scope, including malignant hematology, community practice, and pediatrics. They envisioned SBH playing a crucial role in addressing rising healthcare costs, quality concerns, and disparities in care. They also anticipated the integration of new technologies like artificial intelligence, “virtual” care delivery, and molecular genetics into SBH practice. Conclusions: This study provides valuable insights into the current state of SBH and the need for a standardized curriculum. The findings can inform the development of educational resources and training programs to equip future practitioners with the necessary knowledge and skills to effectively practice SBH and improve hematology care delivery. This study also sheds light on the utility of qualitative research within SBH and the emerging analytical tools that will require further exploration and standardization (e.g., LLM prompt engineering).
Diverse Engraftment Capability of Neuroblastoma Cell Lines in Zebrafish Larvae
Lawrence, Josephine M., Tan, Shyang Hong , Kim, Daniel C. , Tan, Ke‐En , Schroeder, Sydney E., Schaefer, Madison A. , Sosic, Alexis M., Zhu, Shizhen , Yeo, Kok Siong

Mayo Clinic

Zebrafish | September 24, 2024 | Volume: 21 | Issue: 6 | Pages: 385-393

10.1089/zeb.2024.0160 | PMID 39316469 Get It

Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Streiff, Michael B. , Holmstrom, Bjorn, Angelini, Dana E. , Ashrani, Aneel A. , Diep, Robert , Fogerty, Annemarie E., Gallastegui, Nicolas , Gangaraju, Radhika , Rojas‐Hernandez, Cristhiam M. , Goldhaber, Samuel Z. , Kubal, Timothy, Leavitt, Andrew D., Mann, Janelle , Mantha, Simon , Morton, Colleen , Nester, Alex, O’Brien, Andrew , Ranade, M. , Salmasi, Amirali , Schaefer, Jordan K. , Williams, Eliot C., Wun, Theodore, Nguyen, Jamie , Freedman-Cass, Deborah A., Sliker, Bailee , Ashrani, Aneel, Schaefer, Jordan K , Buckner, Tyler W. , Fertrin, Kleber Yotsumoto , Ibrahim, Ibrahim , Leavitt, Andrew D. , Lim, Ming Y , Mann, Janelle, O’Brien, Andrew, Ortel, Thomas L. , Pine, Alexander B. , Pishko, Allyson M. , Wool, Geoffrey D. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 5, 2024 | Volume: 22 | Issue: 7 | Pages: 483-506

10.6004/jnccn.2024.0046 | PMID 39236759 Get It

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology. The content featured in this issue specifically addresses the evaluation and recommended treatment options outlined in the NCCN Guidelines for the diverse subtypes of cancer-associated VTE.
Abstract 4518: Proteolysis targeting chimera (PROTAC)-driven internalization of antibodies targeting oncogenic cell surface receptors
Yang, Lin , Ayers-Ringler, Jennifer , Schaefer-Klein, Janet, Kosari, Farhad , Natarajan, Amar, Tolosa, Ezequiel J. , Mallareddy, Jayapal Reddy , Mansfield, Aaron S.

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 4518-4518

10.1158/1538-7445.am2024-4518 Get It

Abstract Antibody-drug conjugates (ADCs) are increasingly being used in clinic, and many novel ADCs are being tested in clinical trials. Most ADCs act by delivering cytotoxic payloads into target cells. The activity of most ADCs is predicated upon internalization to release the cytotoxic payloads intracellularly to act on the malignant cells. The degree of ADC internalization is incomplete or absent for many cell surface targets, limiting the activity of ADCs. PROTACs are heterobifunctional molecules that result in the polyubiquitylation of their targets by inducing proximity with E3 ligases. The proteasome then recognizes the poly-ubiquitin chains and degrades these targets. We hypothesized that PROTACs that act on the same targets as ADCs could improve the internalization and efficacy of these ADCs. Using multiple cell lines derived from breast, lung or pancreatic cancers that express the oncogenic cell surface proteins EGFR (ERBB1), HER2 (ERBB2) or MET (HGF), we measured antibody internalization with live cell imaging. Antibodies were labeled with a pH sensitive reagent that fluoresces red (640 nm) upon exposure to acidic environments. Fluorescence was measured over time to create an area under the curve which was compared between the cell lines that were treated with and without PROTACs. Antibody internalization was observed in all cell lines that expressed the targets recognized by the antibodies. The addition of PROTACs targeting the same oncogenic cell surface proteins as the antibodies significantly increased antibody internalization beyond that observed without PROTACs. Internalization of antibodies was confirmed by measuring intracellular immunoglobulins by Western blot. Antibody internalization with PROTACs was dose-dependent, increased over time and was blocked by either the clatharin inhibitor Dyngo4a or the proteasome inhibitor MG132. In the case of HER2 for which there are FDA-approved anti-HER2 ADCs, the cytotoxicity of trastuzumab emtansine (TDM1) significantly increased with the addition of a HER2-targeting PROTAC across a range of doses. PROTACs that target the same oncogenic cell surface proteins as antibodies improve antibody internalization and ADC cytotoxicity, in a process dependent upon clatharin and the proteasome. This novel application of PROTACs may impact the use of ADCs, and provides a rationale to combine these agents in clinical trials. Citation Format: Ezequiel J. Tolosa, Lin Yang, Jennifer Ayers-Ringler, Jayapal Mallareddy, Janet Schaefer-Klein, Farhad Kosari, Amar Natarajan, Aaron S. Mansfield. Proteolysis targeting chimera (PROTAC)-driven internalization of antibodies targeting oncogenic cell surface receptors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4518.